ストックスクリーナーアプリを入手
1.30
0.76%
-0.01
前日終値:
$1.31
開ける：
$1.35
24時間の取引高:
1.34M
Relative Volume:
0.68
時価総額：
$161.85M
収益：
$1.55M
当期純損益:
$-63.06M
株価収益率:
-1.6334
EPS:
-0.7959
ネットキャッシュフロー:
$-49.45M
1週間 パフォーマンス:
+2.36%
1か月 パフォーマンス:
-10.96%
6か月 パフォーマンス:
-37.50%
1年 パフォーマンス:
-24.42%
1日の値動き範囲:
$1.30
$1.375
1週間の範囲:
$1.27
$1.42
52週間の値動き範囲:
$1.00
$3.06
Milestone Pharmaceuticals Inc Stock (MIST) Company Profile
名前
Milestone Pharmaceuticals Inc
セクター
電話
(514) 336-0444
住所
1111 BOUL. DR.-FREDERIK-PHILIPS, STE 420, MONTREAL, QC
Compare MIST vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MIST
Milestone Pharmaceuticals Inc
|
1.30 | 161.85M | 1.55M | -63.06M | -49.45M | -0.7959 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Milestone Pharmaceuticals Inc Stock (MIST) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-10 | 開始されました | Raymond James | Strong Buy |
| 2025-12-15 | アップグレード | TD Cowen | Hold → Buy |
| 2025-09-11 | 開始されました | Wells Fargo | Overweight |
| 2025-06-05 | 再開されました | H.C. Wainwright | Buy |
| 2024-08-22 | 開始されました | Rodman & Renshaw | Buy |
| 2023-06-20 | ダウングレード | Jefferies | Buy → Hold |
| 2022-04-22 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2021-03-05 | 開始されました | H.C. Wainwright | Buy |
| 2020-07-29 | アップグレード | Oppenheimer | Perform → Outperform |
| 2020-07-24 | アップグレード | Jefferies | Hold → Buy |
| 2020-03-25 | ダウングレード | Jefferies | Buy → Hold |
| 2020-03-24 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2020-03-24 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2019-06-04 | 開始されました | Oppenheimer | Outperform |
| 2019-06-03 | 開始されました | Cowen | Outperform |
| 2019-06-03 | 開始されました | Jefferies | Buy |
| 2019-06-03 | 開始されました | Piper Jaffray | Overweight |
すべてを表示
Milestone Pharmaceuticals Inc (MIST) 最新ニュース
Milestone Pharmaceuticals (MIST) Investor update Summary - Quartr
Milestone Pharmaceuticals Inc (MIST) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Milestone Pharmaceuticals Inc - TradingKey
Milestone Pharmaceuticals Inc (MIST) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Milestone Pharmaceuticals Inc (MIST) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Milestone Pharmaceuticals Inc (MIST) Institutional Confidence - TradingKey
Milestone Pharmaceuticals Inc (MIST) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Milestone Pharmaceuticals Inc (MIST) Valuation: PE, PB & Fair Value Analysis - TradingKey
Milestone Pharmaceuticals Inc (MIST) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Milestone Pharmaceuticals Faces Financial Challenges amidst Market Shifts - timothysykes.com
Milestone Pharmaceuticals (MIST) investors approve equity plan, elect board and ratify PwC - Stock Titan
Milestone (NASDAQ: MIST) director receives 77,000 stock options grant - Stock Titan
Milestone Pharmaceuticals (MIST) director receives 77,000 stock options at $1.22 strike - Stock Titan
Milestone Pharmaceuticals (MIST) awards director 77,000 stock options - Stock Titan
Milestone Pharmaceuticals (MIST) director receives 77,000 stock options at $1.22 - Stock Titan
Director at Milestone Pharmaceuticals (MIST) receives 77,000 stock options at $1.22 - Stock Titan
Milestone Pharmaceuticals (NASDAQ: MIST) director receives 77,000 stock options grant - Stock Titan
Milestone Pharmaceuticals (MIST) director receives grant of 77,000 stock options - Stock Titan
Milestone Pharmaceuticals: Here Comes The Revenue Ramp (NASDAQ:MIST) - Seeking Alpha
Novartis Canada and the pan-Canadian Pharmaceutical Alliance Achieve Milestone Agreement Enabling Public Reimbursement of (pr)Scemblix® (asciminib tablets) - Newswire Canada
Milestone Pharmaceuticals: Taking The Long View (NASDAQ:MIST) - Seeking Alpha
Eli Lilly scores a first in major pharma milestone - thestreet.com
Heart Rhythm Society and Milestone Pharmaceuticals Partner to Expand SVT Patient Education Through UpBeat.org - PR Newswire
Wockhardt's Zaynich wins US FDA approval, marking milestone in antibiotic innovation - Business Today
Milestone (MIST) Q1 2026 Earnings Transcript - The Globe and Mail
Anti-Aging Cell Therapy Reaches Major GMP Milestone as Wave of Clinical Advancements Gain Momentum - PR Newswire
Analysts Offer Insights on Healthcare Companies: Alpha Tau Medical Ltd (DRTS), Neurogene (NGNE) and Milestone Pharmaceuticals (MIST) - The Globe and Mail
[EFFECT] Milestone Pharmaceuticals Inc. SEC Filing - Stock Titan
Milestone Pharmaceuticals (MIST) Slides 7.24% as Selling Pressure Builds—Key Support at $1.34 in FocusOBV Divergence - thelegaladvocate.com
Milestone Pharmaceuticals Q1 earnings call highlights - MSN
MIST Stock Price, Quote & Chart | MILESTONE PHARMACEUTICALS IN (NASDAQ:MIST) - ChartMill
Supernus Pharmaceuticals to make $33.4 million CVR milestone payment - Investing.com
Milestone reports Q1 results, highlights initial CARDAMYST sales - MSN
Milestone Pharmaceuticals Q1 2026 earnings preview - MSN
Milestone outlines ~2-year phase III AFib-RVR timeline as CARDAMYST launch reaches ~600 prescriptions - MSN
Milestone Pharmaceuticals (MIST) reports Q1 loss, lags revenue estimates - MSN
RTW Investments (MIST) and Roderick Wong disclose 9.99% ownership - Stock Titan
Milestone Pharmaceuticals Inc.'s (NASDAQ:MIST) Path To Profitability - Yahoo Finance
Milestone Pharmaceuticals Inc. (NASDAQ:MIST): Is Breakeven Near? - simplywall.st
MIST Maintained by Wells Fargo -- Price Target Lowered to $7.00 - GuruFocus
Milestone Pharmaceuticals Is Maintained at Overweight by Wells Fargo - Moomoo
Wells Fargo & Company Issues Pessimistic Forecast for Milestone Pharmaceuticals (NASDAQ:MIST) Stock Price - MarketBeat
Milestone Pharmaceuticals Inc.Common Shares (NQ: MIST - FinancialContent
Milestone Pharmaceuticals to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ - The Manila Times
NASDAQ fireside chat: Milestone talks cardiovascular drugs on May 19 - Stock Titan
Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Q1 2026 Earnings Call Transcript - Insider Monkey
Piper Sandler Maintains Milestone Pharmaceuticals(MIST.US) With Buy Rating, Raises Target Price to $7 - Moomoo
Milestone Pharmaceuticals Inc. Q1 2026 10-Q Report: Financial Statements, Risk Factors, and Forward-Looking Statements – Minichart - Minichart
TD Cowen Maintains Milestone Pharmaceuticals(MIST.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Milestone Pharmaceuticals Inc (MIST) Q1 2026 Earnings Call Highl - GuruFocus
Milestone Pharmaceuticals Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Milestone Pharmaceuticals Inc (MIST) 財務データ
収益
当期純利益
現金流量
EPS
0.74%
1.44%
大文字化:
|
ボリューム (24 時間):